MX2023000948A - Proteínas de fusión de citocina doble que comprenden interleucina-10 (il-10). - Google Patents
Proteínas de fusión de citocina doble que comprenden interleucina-10 (il-10).Info
- Publication number
- MX2023000948A MX2023000948A MX2023000948A MX2023000948A MX2023000948A MX 2023000948 A MX2023000948 A MX 2023000948A MX 2023000948 A MX2023000948 A MX 2023000948A MX 2023000948 A MX2023000948 A MX 2023000948A MX 2023000948 A MX2023000948 A MX 2023000948A
- Authority
- MX
- Mexico
- Prior art keywords
- cytokine fusion
- cytokine
- dual
- fusion proteins
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/112—Retroviridae (F), e.g. leukemia viruses
- C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- AIDS & HIV (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063054208P | 2020-07-20 | 2020-07-20 | |
| PCT/US2020/062907 WO2022019945A1 (en) | 2020-07-20 | 2020-12-02 | Dual cytokine fusion proteins comprising il-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000948A true MX2023000948A (es) | 2023-04-14 |
Family
ID=79291996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000948A MX2023000948A (es) | 2020-07-20 | 2020-12-02 | Proteínas de fusión de citocina doble que comprenden interleucina-10 (il-10). |
Country Status (11)
| Country | Link |
|---|---|
| US (19) | US11292822B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4181957A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023534847A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230096959A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116322785A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020459746A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023001187A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3186753A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300062A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023000948A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022019945A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7641912B2 (ja) | 2019-04-19 | 2025-03-07 | シナーキン・ファーマ・ベスローテン・フエンノートシャップ | Il13を含む融合タンパク質 |
| CN116322785A (zh) * | 2020-07-20 | 2023-06-23 | 德卡生物科学公司 | 包含il-10的双细胞因子融合蛋白 |
| JP2024546999A (ja) * | 2021-12-16 | 2024-12-26 | デカ バイオサイエンシーズ, インコーポレイテッド | Il-10を含む二重サイトカイン融合物およびがんを処置するための養子細胞療法または二重特異性t細胞エンゲージャー |
| AU2023225954A1 (en) * | 2022-02-22 | 2024-09-05 | Deka Biosciences, Inc. | Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins |
| IL328577A (en) * | 2023-11-24 | 2026-07-01 | Medpacto Inc | Fusion protein that specifically binds to extradomain b of fibronectin (edb-fn) and transforming growth factor beta (tgfβ) and its use |
| CN122555725A (zh) * | 2024-01-08 | 2026-08-11 | 上药生物治疗(香港)有限公司 | 膜表达il-10及其用途 |
| CN119954974B (zh) * | 2025-04-09 | 2025-07-22 | 四川康德赛医疗科技有限公司 | 一种工程化巨噬细胞,其制备方法及抗纤维化的应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5989867A (en) | 1996-09-23 | 1999-11-23 | Knappe; Andrea | DNA encoding IL-10-like homologue; related reagents |
| WO2001010912A1 (en) * | 1999-08-09 | 2001-02-15 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
| WO2004021861A2 (en) * | 2002-09-03 | 2004-03-18 | Vit Lauermann | Targeted release |
| JP2009536170A (ja) | 2006-05-08 | 2009-10-08 | フィロジェン・エッセペア | 治療用の抗体標的指向サイトカイン |
| WO2008130382A2 (en) | 2006-10-31 | 2008-10-30 | East Carolina University | Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders |
| ES2536772T3 (es) | 2007-09-21 | 2015-05-28 | The Regents Of The University Of California | El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales |
| EP2209805B1 (en) | 2007-10-30 | 2017-09-06 | Philogen S.p.A. | An antigen associated with rheumatoid arthritis |
| AU2009298131B2 (en) | 2008-10-02 | 2016-07-14 | Aptevo Research And Development Llc | CD86 antagonist multi-target binding proteins |
| JP2013534813A (ja) * | 2010-05-26 | 2013-09-09 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 抗cd133抗体一本鎖可変断片、及びこれらの使用 |
| WO2012045334A1 (en) | 2010-10-05 | 2012-04-12 | Synthon Bv | Biologically active il-10 fusion proteins |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| ES2872964T3 (es) | 2011-07-27 | 2021-11-03 | Philogen Spa | Inmunoconjugado de IL-12 |
| CN104245719B (zh) | 2011-12-12 | 2016-09-14 | 宾夕法尼亚大学托管会 | 包含改进的il-12基因构建体的组合物和疫苗、免疫治疗剂及其使用方法 |
| US20150038678A1 (en) | 2012-02-29 | 2015-02-05 | Ambrx, Inc. | Interleukin-10 Polypeptide Conjugates and Their Uses |
| US9346872B2 (en) * | 2012-08-08 | 2016-05-24 | Roche Glycart Ag | Interleukin-10 fusion proteins |
| EP2903629B1 (en) * | 2012-10-03 | 2019-07-10 | Philogen S.p.A. | Antibody conjugate for use in treating inflammatory bowel disease |
| WO2014153056A2 (en) | 2013-03-14 | 2014-09-25 | Parkash Gill | Cancer treatment using antibodies that bing cell surface grp78 |
| JP2016519111A (ja) | 2013-04-26 | 2016-06-30 | フィロゲン エスピーエー | 細胞外マトリックス成分に対する抗体にコンジュゲートしたil4 |
| BR112016016658A2 (pt) | 2014-02-06 | 2018-01-23 | F. Hoffmann-La Roche Ag | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão |
| IL300029A (en) | 2014-05-16 | 2023-03-01 | Baylor Res Institute | Methods and preparations for the treatment of autoimmune and inflammatory conditions |
| CN104403004B (zh) | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| EP3233920B1 (en) | 2014-12-19 | 2020-08-26 | Alkermes, Inc. | Single chain fc fusion proteins |
| WO2016191587A1 (en) | 2015-05-28 | 2016-12-01 | Armo Biosciences, Inc. | Pegylated interleukin-10 for use in treating cancer |
| KR101811050B1 (ko) | 2015-09-02 | 2017-12-21 | 경북대학교 산학협력단 | 항염증성 폴리펩티드와 페리틴 모노머 단편이 접합된 융합폴리펩티드 및 이를 유효성분으로 포함하는 염증성 질환 예방 및 치료용 약학적 조성물 |
| WO2017091611A1 (en) | 2015-11-23 | 2017-06-01 | Immungene, Inc | Enhanced cancer immunotherapy using antibody-interferon fusion molecules |
| US10144768B2 (en) | 2015-12-04 | 2018-12-04 | Novartis Ag | Antibody cytokine engrafted compositions and methods of use for immunoregulation |
| CN106349393B (zh) * | 2015-12-21 | 2020-10-30 | 合肥立方制药股份有限公司 | 一种增强抗体药物稳定性的结构 |
| WO2017178562A1 (en) | 2016-04-12 | 2017-10-19 | Philogen S.P.A. | Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (car)-t cell |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| WO2018156791A1 (en) | 2017-02-22 | 2018-08-30 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
| WO2018213335A1 (en) * | 2017-05-16 | 2018-11-22 | Scalmibio, Inc. | Activatable antibodies and methods of use thereof |
| WO2019201866A1 (en) * | 2018-04-16 | 2019-10-24 | Swedish Orphan Biovitrum Ab (Publ) | Fusion protein |
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| CN114072164A (zh) * | 2019-03-06 | 2022-02-18 | 德卡生物科学公司 | Il-10变体分子和治疗炎性疾病和肿瘤的方法 |
| EP4087947A4 (en) * | 2020-01-09 | 2024-05-01 | Deka Biosciences, Inc. | METHODS OF USING GENETIC MARKERS, SNPS AND/OR INDELS TO DETERMINE SENSITIVITY TO IL-10 TREATMENT |
| CN115867275A (zh) | 2020-04-13 | 2023-03-28 | 大学健康网络 | 治疗细胞因子释放综合征的方法 |
| CN116322785A (zh) | 2020-07-20 | 2023-06-23 | 德卡生物科学公司 | 包含il-10的双细胞因子融合蛋白 |
| KR20240007204A (ko) | 2021-05-11 | 2024-01-16 | 싱가포르 헬스 서비시즈 피티이 엘티디 | 키메라 항원 수용체 및 이를 포함하는 변형된 세포 |
| KR20240156653A (ko) | 2021-12-13 | 2024-10-30 | 데카 바이오사이언시즈, 인크. | 다중-서브유닛 시토카인을 포함하는 이중 시토카인 융합 단백질 |
| JP2024546999A (ja) | 2021-12-16 | 2024-12-26 | デカ バイオサイエンシーズ, インコーポレイテッド | Il-10を含む二重サイトカイン融合物およびがんを処置するための養子細胞療法または二重特異性t細胞エンゲージャー |
| AU2023225954A1 (en) | 2022-02-22 | 2024-09-05 | Deka Biosciences, Inc. | Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins |
-
2020
- 2020-12-02 CN CN202080105253.9A patent/CN116322785A/zh active Pending
- 2020-12-02 AU AU2020459746A patent/AU2020459746A1/en active Pending
- 2020-12-02 WO PCT/US2020/062907 patent/WO2022019945A1/en not_active Ceased
- 2020-12-02 KR KR1020237005848A patent/KR20230096959A/ko not_active Ceased
- 2020-12-02 BR BR112023001187A patent/BR112023001187A2/pt unknown
- 2020-12-02 CA CA3186753A patent/CA3186753A1/en active Pending
- 2020-12-02 IL IL300062A patent/IL300062A/en unknown
- 2020-12-02 MX MX2023000948A patent/MX2023000948A/es unknown
- 2020-12-02 JP JP2023504420A patent/JP2023534847A/ja active Pending
- 2020-12-02 EP EP20946024.5A patent/EP4181957A4/en active Pending
-
2021
- 2021-03-11 US US17/199,239 patent/US11292822B2/en active Active
-
2022
- 2022-03-01 US US17/684,243 patent/US11629178B2/en active Active
- 2022-03-01 US US17/684,205 patent/US11608368B2/en active Active
- 2022-03-01 US US17/684,229 patent/US12268903B2/en active Active
- 2022-03-01 US US17/684,272 patent/US11618775B2/en active Active
- 2022-03-01 US US17/684,106 patent/US11572397B2/en active Active
- 2022-03-01 US US17/684,151 patent/US11613563B2/en active Active
- 2022-03-01 US US17/684,290 patent/US12263358B2/en active Active
-
2023
- 2023-11-03 US US18/501,856 patent/US12116391B2/en active Active
- 2023-11-03 US US18/501,741 patent/US12121755B2/en active Active
- 2023-11-03 US US18/501,571 patent/US12145007B2/en active Active
- 2023-11-03 US US18/501,762 patent/US12006346B2/en active Active
- 2023-11-03 US US18/501,584 patent/US12122814B2/en active Active
- 2023-11-03 US US18/501,561 patent/US12116389B2/en active Active
- 2023-11-03 US US18/501,581 patent/US12110317B2/en active Active
- 2023-11-03 US US18/501,914 patent/US12116393B2/en active Active
- 2023-11-03 US US18/501,850 patent/US12116390B2/en active Active
- 2023-11-03 US US18/501,884 patent/US12116392B2/en active Active
-
2024
- 2024-10-08 US US18/909,739 patent/US20250135241A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024007270A (es) | Proteinas de fusion de citocinas duales que comprenden citocinas de multiples subunidades. | |
| BR112023001187A2 (pt) | Proteínas de fusão de citocina dupla compreendendo il -10 | |
| EA201992765A1 (ru) | Белки на основе антител с привитым цитокином и способы их применения в лечении рака | |
| WO2023115033A3 (en) | Dual cytokine fusions comprising il-10 and adoptive cell therapies or bispecific t-cell engagers to treat cancer | |
| WO2021181233A3 (en) | Cd80-fc fusion protein and uses thereof | |
| AU2015255979B2 (en) | Using B-cell-targeting antigen IgG fusion as tolerogenic protein therapy for treating adverse immune responses | |
| MY208638A (en) | Anti-steap1 antigen-binding protein | |
| PH12023552763A1 (en) | Agonistic anti-il-2r antibodies and methods of use | |
| MX2023001556A (es) | Anticuerpos que se dirigen a egfr y uso de los mismos. | |
| EP4623992A3 (en) | Antibodies specifically binding to human il-1r7 | |
| RU2018106876A (ru) | Новая комбинация для применения при лечении злокачественного новообразования | |
| FI3978522T3 (fi) | Humaaneja vasta-aineita Fel d1:lle ja niiden käyttömenetelmiä | |
| EA202092162A1 (ru) | Антитела против cxcl13 для лечения аутоиммунных заболеваний и рака | |
| UA130540C2 (uk) | Композиція антитіла b7-h4 | |
| BR112023016574A2 (pt) | Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão | |
| JOP20220070A1 (ar) | مترافقات جسم مضاد- عقار مضاد لميزوثيلين إيريبولين وطرق استخدامها | |
| MX2022005850A (es) | Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo. | |
| WO2021076554A8 (en) | Antibodies targeting flt3 and use thereof | |
| EP4610275A3 (en) | Anti-pd-1 antibodies and fusion proteins | |
| WO2022038417A3 (en) | Modified il-18 polypeptides and uses thereof | |
| EA201890805A1 (ru) | Биспецифические антитела против cd3*cd19 | |
| MX2025002112A (es) | Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso | |
| WO2021226163A3 (en) | Antibodies targeting clec12a and use thereof | |
| MX2023002106A (es) | Anticuerpos fgfr3 y metodos de uso. | |
| WO2021231741A3 (en) | Anti-pd-l1 antibodies and anti-pd-l1/il10 fusion proteins |